More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$99.08B
EPS
45.21
P/E ratio
18.4
Price to sales
4.95
Dividend yield
0.393%
Beta
0.098446
Previous close
$952.40
Today's open
$952.56
Day's range
$946.94 - $965.48
52 week range
$591.52 - $991.73
show more
CEO
Leonard S. Schleifer
Employees
15410
Headquarters
Tarrytown, NY
Exchange
Nasdaq Global Select
Shares outstanding
103447859
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
US FDA approves Regeneron's drug for generalized myasthenia gravis
US FDA approves Regeneron's drug for generalized myasthenia gravis
Reuters • 40 minutes ago

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
GlobeNewsWire • an hour ago

Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.
Zacks Investment Research • 4 hours ago

Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval
Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.
MarketBeat • Nov 17, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
Approval introduces an extended dosing regimen of Libtayo 700 mg given every six weeks, following initial 12 weeks of treatment with Libtayo 350 mg every three weeks Also approved is an option of reducing subsequent infusion times of Libtayo 350 mg by up to half, from 30 minutes to 15 minutes, after a well-tolerated 30-minute infusion TARRYTOWN, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved an alternative, flexible dosing schedule for Libtayo® (cemiplimab) across all approved skin, lung and cervical cancer indications.
GlobeNewsWire • Nov 17, 2026

REGN Price Forecast: Rally Faces Resistance After 37% Advance
Regeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.
FXEmpire • Nov 16, 2026

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
Regeneron sells 16 products, and they have helped revenue climb in recent years. The company's leading products delivered record revenue in the third quarter.
The Motley Fool • Nov 14, 2026

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma volume expansion, the intended effect of NPR1 blockade Potentially pivotal Phase 3 trial planned for first half of 2027 TARRYTOWN, N.Y., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome (POTS) evaluating baloncibart, a novel, investigational, first-in-class monoclonal antibody that blocks natriuretic peptide receptor 1 (NPR1).
GlobeNewsWire • Nov 12, 2026

REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?
Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.
Zacks Investment Research • Nov 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Regeneron Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.